Structural Heart最新文献

{"title":"Utilization of 3-Dimensional Print Technology and 4-Dimensional Intracardiac Echocardiography (ICE) Imaging to Manage Left Atrial Appendage Occlusion Peridevice Leak","authors":"Kifah Hussain MD, Christopher Ding MD, Jose Nazari MD, Mark Metzl MD, Amit Pursnani MD, Jonathan R. Rosenberg MD","doi":"10.1016/j.shj.2023.100263","DOIUrl":"10.1016/j.shj.2023.100263","url":null,"abstract":"","PeriodicalId":36053,"journal":{"name":"Structural Heart","volume":"8 2","pages":"Article 100263"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2474870623001999/pdfft?md5=57b302b4b26eafdbaa21303bc786f8cb&pid=1-s2.0-S2474870623001999-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138624100","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bicuspid Aortic Valve Disease: Classifications, Treatments, and Emerging Transcatheter Paradigms","authors":"Ankur Kalra MD ,&nbsp;Rajiv Das MB ChB, MD ,&nbsp;Mohammad Alkhalil MD, DPhil ,&nbsp;Iryna Dykun MD ,&nbsp;Alessandro Candreva MD ,&nbsp;Omar Jarral MBBS, PhD ,&nbsp;Syed M. Rehman MBBS ,&nbsp;Monil Majmundar MD ,&nbsp;Kunal N. Patel MD, MPH ,&nbsp;Josep Rodes-Cabau MD, PhD ,&nbsp;Michael J. Reardon MD ,&nbsp;Rishi Puri MBBS, PhD","doi":"10.1016/j.shj.2023.100227","DOIUrl":"10.1016/j.shj.2023.100227","url":null,"abstract":"<div><p>Bicuspid aortic valve (BAV) is a common congenital valvular malformation, which may lead to early aortic valve disease and bicuspid-associated aortopathy. A novel BAV classification system was recently proposed to coincide with transcatheter aortic valve replacement being increasingly considered in younger patients with symptomatic BAV, with good clinical results, yet without randomized trial evidence. Procedural technique, along with clinical outcomes, have considerably improved in BAV patients compared with tricuspid aortic stenosis patients undergoing transcatheter aortic valve replacement. The present review summarizes the novel BAV classification systems and examines contemporary surgical and transcatheter approaches.</p></div>","PeriodicalId":36053,"journal":{"name":"Structural Heart","volume":"8 1","pages":"Article 100227"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2474870623001215/pdfft?md5=93079ca2ca249d6eaa2d1b94f957330a&pid=1-s2.0-S2474870623001215-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136093462","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"FAcilitating Safe Trans-femoral ACCESS for Transcatheter Aortic Valve Replacement in High Body Mass Index Patients—The FAST-ACCESS Cohort Study","authors":"Sarosh Khan MBBS ,&nbsp;Rohan Jagathesan MD ,&nbsp;Olivia M.T. Frost BSc ,&nbsp;Iveta Crawford BSc ,&nbsp;Sheila Smith BSc ,&nbsp;Swamy Gedela MBBS ,&nbsp;Samer Fawaz BMBS ,&nbsp;Rupert Simpson MBChB ,&nbsp;Arvind Singh MBBS ,&nbsp;Grigoris V. Karamasis MD ,&nbsp;Thomas R. Keeble MD ,&nbsp;John R. Davies PhD ,&nbsp;Alamgir Kabir PhD ,&nbsp;Rajesh Aggarwal MD ,&nbsp;Christopher M. Cook PhD","doi":"10.1016/j.shj.2023.100232","DOIUrl":"10.1016/j.shj.2023.100232","url":null,"abstract":"","PeriodicalId":36053,"journal":{"name":"Structural Heart","volume":"8 1","pages":"Article 100232"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2474870623001264/pdfft?md5=46512dd7e8b92e151d78af533f92b1cb&pid=1-s2.0-S2474870623001264-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139304193","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Differential Impact of Blood Pressure Control Targets on Epicardial Coronary Flow After Transcatheter Aortic Valve Replacement","authors":"Brennan J. Vogl BS ,&nbsp;Alejandra Chavez-Ponce MD ,&nbsp;Adam Wentworth MS ,&nbsp;Eric Erie AAS ,&nbsp;Pradeep Yadav MD ,&nbsp;Vinod H. Thourani MD ,&nbsp;Lakshmi Prasad Dasi PhD ,&nbsp;Brian Lindman MD, MSc ,&nbsp;Mohamad Alkhouli MD ,&nbsp;Hoda Hatoum PhD","doi":"10.1016/j.shj.2023.100230","DOIUrl":"10.1016/j.shj.2023.100230","url":null,"abstract":"<div><h3>Background</h3><p>The cause for the association between increased cardiovascular mortality rates and lower blood pressure (BP) after aortic valve replacement (AVR) is unclear. This study aims to assess how the epicardial coronary flow (ECF) after AVR varies as BP levels are changed in the presence of a right coronary lesion.</p></div><div><h3>Methods</h3><p>The hemodynamics of a 3D printed aortic root model with a SAPIEN 3 26 deployed were evaluated in an <em>in vitro</em> left heart simulator under a range of varying systolic blood pressure (SBP) and diastolic blood pressure (DBP). ECF and the flow ratio index were calculated. Flow index value &lt;0.8 was considered a threshold for ischemia.</p></div><div><h3>Results</h3><p>As SBP decreased, the average ECF decreased below the physiological coronary minimum at 120 mmHg. As DBP decreased, the average ECF was still maintained above the physiological minimum. The flow ratio index was &gt;0.9 for SBP ≥130 mmHg. However, at an SBP of 120 mmHg, the flow ratio was 0.63 (<em>p</em> ≤ 0.0055). With decreasing DBP, no BP condition yielded a flow ratio index that was less than 0.91.</p></div><div><h3>Conclusions</h3><p>Reducing BP to the current recommended levels assigned for the general population after AVR in the presence of coronary artery disease may require reconsideration of levels and treatment priority. Additional studies are needed to fully understand the changes in ECF dynamics after AVR in the presence and absence of coronary artery disease.</p></div>","PeriodicalId":36053,"journal":{"name":"Structural Heart","volume":"8 1","pages":"Article 100230"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2474870623001240/pdfft?md5=f196d452263fee2a8a6454519e119567&pid=1-s2.0-S2474870623001240-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135714264","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editor’s Page: What Ever Happened to the Physical Examination?","authors":"Anthony DeMaria MD","doi":"10.1016/j.shj.2023.100265","DOIUrl":"https://doi.org/10.1016/j.shj.2023.100265","url":null,"abstract":"","PeriodicalId":36053,"journal":{"name":"Structural Heart","volume":"8 1","pages":"Article 100265"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2474870623002014/pdfft?md5=4ecedeae1bb8692e0996aacf8804b466&pid=1-s2.0-S2474870623002014-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139487896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diastolic Dysfunction and Health Status Outcomes After Transcatheter Aortic Valve Replacement","authors":"Rayan S. El-Zein DO ,&nbsp;Ali O. Malik MD, MSc ,&nbsp;David J. Cohen MD, MSc ,&nbsp;John A. Spertus MD, MPH ,&nbsp;John T. Saxon MD ,&nbsp;Philippe Pibarot DVM, PhD ,&nbsp;Rebecca T. Hahn MD ,&nbsp;Maria C. Alu MS ,&nbsp;Kan Shang PhD ,&nbsp;Susheel K. Kodali MD ,&nbsp;Vinod H. Thourani MD ,&nbsp;Martin B. Leon MD ,&nbsp;Michael J. Mack MD ,&nbsp;Adnan K. Chhatriwalla MD","doi":"10.1016/j.shj.2023.100225","DOIUrl":"10.1016/j.shj.2023.100225","url":null,"abstract":"<div><h3>Background</h3><p>Baseline left ventricular diastolic dysfunction (LVDD) is associated with poor health status in patients with severe aortic stenosis undergoing transcatheter aortic valve replacement (TAVR), but health status improvement after TAVR appears similar across all grades of LVDD. Here, we aim to examine the relationship between changes in LVDD severity and health status outcomes following TAVR.</p></div><div><h3>Methods</h3><p>Patients who underwent TAVR and had evaluable LVDD at both baseline and 1 year in the PARTNER (Placement of Aortic Transcatheter Valves) 2 SAPIEN 3 registries and PARTNER 3 trial were analyzed. LVDD grade was evaluated using echocardiography core lab data and an adapted definition of American Society of Echocardiography guidelines. Health status was assessed using the Kansas City Cardiomyopathy Questionnaire Overall Summary (KCCQ-OS) score. The association between ΔLVDD severity and ΔKCCQ-OS was examined using linear regression models adjusted for baseline KCCQ-OS.</p></div><div><h3>Results</h3><p>Of 1100 patients, 724 (65.8%), 283 (25.7%), and 93 (8.5%) had grade 0/1, 2, and 3 LVDD at baseline, respectively. At 1 year, LVDD severity was unchanged in 790 (71.8%) patients, improved in 189 (17.2%), and worsened in 121 (11.0%). Among 376 patients with baseline grade 2 or 3 LVDD, 50.3% had improvement in LVDD. In the overall cohort, KCCQ-OS score improved by 21.9 points at 1 year. There was a statistically significant association between change in LVDD severity (improved, unchanged, and worsened) and ΔKCCQ-OS at 1 year (<em>p</em> = 0.007).</p></div><div><h3>Conclusions</h3><p>Change in LVDD grade was associated with change in health status 1 year following TAVR.</p></div>","PeriodicalId":36053,"journal":{"name":"Structural Heart","volume":"8 1","pages":"Article 100225"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2474870623001197/pdfft?md5=0df734ee94938f42b4ed59284422c523&pid=1-s2.0-S2474870623001197-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134994979","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"First Report of Evolut Pro+ Transcatheter Aortic Valve-in-Valve in a Degenerated Lotus Valve","authors":"Thorald Stolte BSc ,&nbsp;David Winkel MD ,&nbsp;Philip Haaf MD ,&nbsp;Thomas Nestelberger MD","doi":"10.1016/j.shj.2023.100229","DOIUrl":"10.1016/j.shj.2023.100229","url":null,"abstract":"<div><p>The increasing use of transcatheter aortic valves in patients with aortic stenosis has led to a higher number of valve-in-valve procedures due to gradual valve degeneration. We present a case of a 72-year-old woman who received transcatheter aortic valve implantation (TAVI) using a Lotus valve due to severe aortic stenosis, which showed valve degeneration several years after the initial procedure. After heart-team discussion, TAVI-in-TAVI was planned using an Evolut pro+ valve, which allowed for full coverage of the Lotus valve and maintenance of coronary flow, resulting in a well-functioning valve with no regurgitation and normal performance. Despite high-risk anatomic features, valve-in-valve using an Evolut pro+ in a degenerated Lotus valve is feasible and overcomes pitfalls such as entanglement or coronary obstruction.</p></div>","PeriodicalId":36053,"journal":{"name":"Structural Heart","volume":"8 1","pages":"Article 100229"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2474870623001239/pdfft?md5=93bb4aaaa4d692aae5398e3c03b53b46&pid=1-s2.0-S2474870623001239-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135664301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Valve Hemodynamics by Valve Size and 1-Year Survival Following Implantation of the Portico Valve in the Multicenter CONFIDENCE Registry","authors":"Helge Möllmann MD ,&nbsp;Axel Linke MD ,&nbsp;Luis Nombela-Franco MD ,&nbsp;Martin Sluka MD ,&nbsp;Juan Francisco Oteo Dominguez MD ,&nbsp;Matteo Montorfano MD ,&nbsp;Won-Keun Kim MD ,&nbsp;Martin Arnold MD ,&nbsp;Mariuca Vasa-Nicotera MD ,&nbsp;Stephan Fichtlscherer MD ,&nbsp;Lenard Conradi MD ,&nbsp;Anthony Camuglia MD ,&nbsp;Francesco Bedogni MD ,&nbsp;Keshav Kohli PhD ,&nbsp;Ganesh Manoharan MD","doi":"10.1016/j.shj.2023.100226","DOIUrl":"10.1016/j.shj.2023.100226","url":null,"abstract":"<div><h3>Background</h3><p>The CONtrolled delivery For ImproveD outcomEs with cliNiCal Evidence registry was initiated to characterize the clinical safety and device performance from experienced transcatheter aortic valve implantation (TAVI) centers in Europe and Australia that use the Portico valve to treat patients with severe aortic stenosis. We herein report for the first time the valve performance at 30-day across all implanted valve sizes and the 1-year survival from this registry.</p></div><div><h3>Methods</h3><p>This was a prospective, multicenter, single-arm observational clinical investigation of patients clinically indicated for implantation of a Portico valve in experienced TAVI centers. Patients were treated with a commercially available valve (size 23, 25, 27, or 29 mm) using either the first-generation delivery system (DS) (n = 501) or the second-generation (FlexNav) DS (n = 500). Adverse events were adjudicated by an independent clinical events committee according to Valve Academic Research Consortium-2 criteria. Echocardiographic outcomes were assessed at 30 days by an independent core laboratory, and a survival check was performed at 1 year.</p></div><div><h3>Results</h3><p>We enrolled 1001 patients (82.0 years, 62.5% female, 63.7% New York Heart Association functional class III/IV at baseline) from 27 clinical sites in 8 countries across Europe and one site in Australia. Implantation of a single valve was successful in 97.5% of subjects. Valve hemodynamics at 30 days were substantially improved relative to baseline, with large aortic valve areas and low mean gradients across all implanted valve sizes (aortic valve areas were 1.7 ± 0.4, 1.7 ± 0.5, 1.8 ± 0.5, and 2.0 ± 0.5 cm², and mean gradients were 7.0 ± 2.7, 7.5 ± 4.7, 7.3 ± 3.3, and 6.4 ± 3.3 mmHg for 23, 25, 27, and 29 mm valve sizes, respectively). Across all implanted valve sizes, most patients (77.1%) had no patient-prosthesis mismatch. Death from any cause within 1 year occurred in 13.7% of the patients in the first-generation DS group as compared with 11.0% in the second-generation DS group (<em>p</em> = 0.2).</p></div><div><h3>Conclusions</h3><p>The Portico valve demonstrated excellent hemodynamic performance across all valve sizes in a large cohort of subjects implanted in experienced TAVI centers. One-year survival rates were favorable when using both the first-generation and second-generation (FlexNav) DSs in this high-risk cohort.</p></div><div><h3>ClinicalTrials.gov Identifier</h3><p><span>NCT03752866</span><svg><path></path></svg>.</p></div>","PeriodicalId":36053,"journal":{"name":"Structural Heart","volume":"8 1","pages":"Article 100226"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2474870623001203/pdfft?md5=211889f1e1a588eaef28eddf44b5194a&pid=1-s2.0-S2474870623001203-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135664303","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Ozaki Procedure: Standardized Protocol Adoption of a Complex Innovative Procedure","authors":"Viral Patel MD ,&nbsp;Shinya Unai MD ,&nbsp;Ryan Moore MD ,&nbsp;Habib Layoun MD ,&nbsp;Serge Harb MD ,&nbsp;Michael Z.Y. Tong MD ,&nbsp;Tara Karamlou MD ,&nbsp;Hani K. Najm MD ,&nbsp;Lars G. Svensson MD, PhD ,&nbsp;Jeevanantham Rajeswaran PhD ,&nbsp;Eugene H. Blackstone MD ,&nbsp;Gösta B. Pettersson MD, PhD","doi":"10.1016/j.shj.2023.100217","DOIUrl":"10.1016/j.shj.2023.100217","url":null,"abstract":"<div><h3>Background</h3><p>The Ozaki procedure using autologous pericardium is an interesting but complex alternative for aortic valve replacement. We present a standardized approach to minimize the learning curve and confirm reproducibility.</p></div><div><h3>Methods</h3><p>After careful preparation, from May 2015 to February 2021, an Ozaki procedure was performed on 46 patients age 51 ± 14 years. Seven had unicuspid (15%), 29 bicuspid (63%), and 10 tricuspid (22%) aortic valves, and 2 patients had endocarditis. Endpoints were operative learning curves, perioperative outcomes, intermediate-term valve hemodynamics, reintervention, health-related quality of life (MacNew Heart Disease Health-Related Quality of Life questionnaire), and mortality.</p></div><div><h3>Results</h3><p>Cardiopulmonary bypass and aortic clamp times decreased from 145 to 125 ​minutes and 120 to 100 ​minutes, respectively, over the first 20 cases, reflecting the learning curve. There was no major perioperative morbidity or mortality. Median postoperative stay was 6.9 days. Aortic regurgitation was mild or less in all but 2 patients who developed moderate aortic regurgitation. Mean aortic valve gradient was 7.9 mmHg postoperatively, 9.2 mmHg by 6 months, and constant thereafter. Left ventricular ejection fraction was 58% preoperatively, 60% at 6 months, and remained stable thereafter. One patient developed infective endocarditis 7 months postoperatively, failed medical management, and underwent valve replacement at 14 months. Two-year survival was 96%, with 1 noncardiac death at 16 months. Health-related quality of life in mental, physical, and emotional domains was better than matched norms, global 6.2 vs. 5.0 (<em>p</em> &lt; 0.0001).</p></div><div><h3>Conclusions</h3><p>Using a well-prepared standardized approach, the Ozaki procedure is reproducible with a short learning curve, excellent hemodynamic performance, and good quality of life.</p></div>","PeriodicalId":36053,"journal":{"name":"Structural Heart","volume":"8 1","pages":"Article 100217"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2474870623001033/pdfft?md5=c066851c361ab67e9d5348b0c5dd1fd4&pid=1-s2.0-S2474870623001033-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135705795","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mitral Transcatheter Edge-to-Edge Repair With the PASCAL Precision System: Device Knobology and Review of Advanced Steering Maneuvers","authors":"Santiago Garcia MD ,&nbsp;Sammy Elmariah MD ,&nbsp;Robert J. Cubeddu MD ,&nbsp;Firas Zahr MD ,&nbsp;Mackram F. Eleid MD ,&nbsp;Susheel K. Kodali MD ,&nbsp;Puvi Seshiah MD ,&nbsp;Rahul Sharma MD ,&nbsp;D. Scott Lim MD","doi":"10.1016/j.shj.2023.100234","DOIUrl":"10.1016/j.shj.2023.100234","url":null,"abstract":"<div><p>In 2022, the Food and Drug Administration approved a second mitral transcatheter edge-to-edge repair device for the treatment of primary mitral regurgitation (PASCAL Precision Transcatheter Valve Repair System, Edwards Lifesciences, Irvine, CA). The PASCAL Precision system consists of a guide sheath, implant system, and accessories. The implant system consists of a steerable catheter, an implant catheter, and the implant (PASCAL or PASCAL Ace). The guide sheath and steerable catheter move and flex independently from each other and are not keyed, allowing for freedom of rotation in three dimensions. This manuscript provides an overview of the PASCAL Precision system and describes the basic and advanced steering maneuvers to facilitate effective and safe mitral transcatheter edge-to-edge repair.</p></div>","PeriodicalId":36053,"journal":{"name":"Structural Heart","volume":"8 1","pages":"Article 100234"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2474870623001288/pdfft?md5=de24dd5f4c359f0b717255587e9e9ca5&pid=1-s2.0-S2474870623001288-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139305785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}